← Back to Search

A Non-Pharmacological Method for Enhancing Sleep in PTSD

N/A
Waitlist Available
Led By William Killgore, Ph.D.
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up results 6 weeks post-treatment

Summary

Sleep disturbance is nearly ubiquitous among individuals suffering from PTSD and is a major problem among service members returning from combat deployments. The proposed study aims to test a novel, inexpensive, and easy to use approach to improving sleep among service members with PTSD. Primary outcome measures will include not only PTSD symptom improvement but also include neuroimaging of brain structure, function, connectivity, and neurochemistry changes. The proposal is firmly grounded in the emerging scientific literature regarding sleep, light exposure, brain function, anxiety, and resilience. Prior evidence suggests that bright light therapy is effective for improving mood and fatigue, and our pilot data further suggest that this treatment may be effective for improving daytime sleepiness and brain functioning in brain injured individuals. Thus, this intervention, in our own research and in the work of others, has been shown to affect critical sleep regulatory systems. Improving sleep may be a vital component of recovery in these service members. Our approach would directly address this issue. Our preliminary data have shown that this approach is extremely well tolerated and is effective for improving sleep, mood, cognitive performance, and brain function among individuals with brain injuries. Finally, the potential impact of this study is high because of the capability of transitioning the research to direct clinical application almost immediately. If the bright light treatment is demonstrated as effective, this approach would be readily available for nearly immediate large-scale implementation, as the devices have been widely used for years in other contexts, are already safety tested, and commercially available from several manufacturers for a very low cost. Thus, the impact of this research on treating PTSD would be high and immediate.

Eligible Conditions
  • Post-Traumatic Stress Disorder
  • Sleep Disorders

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~results 6 weeks post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and results 6 weeks post-treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Daytime Sleepiness (ESS)
Daytime Sleepiness (MSLT)
Daytime Sleepiness (SSS)
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PTSD wavelength-1 bright lightExperimental Treatment1 Intervention
30 minutes of daily light exposure for 6 weeks
Group II: PTSD wavelength-2 bright lightPlacebo Group1 Intervention
30 minutes of daily light exposure for 6 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PTSD wavelength-1 bright light
2014
N/A
~90

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
539 Previous Clinical Trials
161,586 Total Patients Enrolled
U.S. Army Medical Research Acquisition ActivityFED
23 Previous Clinical Trials
8,327 Total Patients Enrolled
William Killgore, Ph.D.Principal InvestigatorUniversity of Arizona
~8 spots leftby Dec 2025